Abstract

Leishmaniasis comprises a group of diseases caused by protozoan parasites of the genus Leishmania transmitted by the bite of a hematophagous vector insect. This complex group of diseases depending on the infecting Leishmania species and the host's immune system, can cause ulcerative skin lesions, disfiguring muco-cutaneous lesions, to a visceral form causing death. The main tool in the treatment of the different clinical forms of leishmaniasis have been pentavalent antimonials in doses of 20 mg / kg per day for 20 days with an efficacy close to 85%. This treatment is painful and highly toxic, many patients do not finish the treatment, which favors the reactivation of the lesion, the compromise in the mucosa and the appearance of resistance. In this sense, it is intended that one of the treatments for skin lesions be applied topically, however, to date this treatment does not exist. In this work, a review has been carried out on the preclinical and clinical trials of topical treatments for Cutaneous Leishmaniasis in the databases Lilacs and pubmed, having 36 articles for the total review and finding an efficiency in most of them

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.